Mallinckrodt closes Therakos acquisition

CHESTERFIELD, U.K. — Specialty biopharmaceutical company Mallinckrodt announced Monday that it had closed on its $1.3 billion acquisition of Therakos Immunotherapy.

“We are pleased to welcome the Therakos team to Mallinckrodt and look forward to integrating their commercial operations into the critical care organization within our Hospital Specialty Brands business,” Mallinckrodt president and CEO Mark Trudeau said.

Mallinckrodt expects the deal to be accretive by about $0.10 per share on its diluted FY2016 earnings and increasingly accretive in subsequent years. Mallinckrodt is also expecting $185 million to $195 million in net sales for Therako products in FY2015, with growth in subsequent years.

“In the past two years we've transformed Mallinckrodt into a leading specialty biopharmaceutical company built on highly durable growth platforms with a broad and diverse product portfolio, and this acquisition continues that journey,” Trudeau said.